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Abstract
Background: Aging and HIV infection are independently associated with excessive immune activation and impaired
immune responses to vaccines, but their relationships have not been examined.
Methods: For selecting an aging population we enrolled 28 post-menopausal women including 12 healthy volunteers
and 16 HIV-infected women on antiretroviral treatment with <100 HIV RNA copies/ml. Antibody titers to trivalent
influenza vaccination given during the 2011-2012 season were determined before and 4 weeks after vaccination.
Results: Seroprotective influenza antibody titers (≥1:40) were observed in 31% HIV+ and 58% HIV-uninfected
women pre-vaccination. Following vaccination, magnitude of antibody responses and frequency of seroprotection
were lower in HIV+ (75%) than in HIV– (91%) women. Plasma IL-21, the signature cytokine of T follicular helper cells
(Tfh), and CD4 T cell IL-21R were upregulated with seroconversion (≥4 fold increase in antibody titer). Post-vaccine
antibody responses were inversely correlated with pre-vaccination plasma TNFα levels and with activated CD4 T
cells, including activated peripheral (p)Tfh. Plasma TNFα levels were correlated with activated pTfh cells (r=0.48,
p=0.02), and inversely with the post-vaccination levels of plasma IL-21 (r=-0.53, p=0.02). In vitro TNFα blockade
improved the ability of CD4 T cells to produce IL-21 and of B cells to secrete immunoglobulins, and addition of
exogenous IL-21 to cell cultures enhanced B cell function. Higher frequencies of activated and exhausted CD8 T and
B cells were noted in HIV+ women, but these markers did not show a correlation with antibody responses.
Conclusions: In aging HIV-infected and uninfected women, activated CD4 and pTfh cells may compromise influenza
vaccine-induced antibody response, for which a mechanism of TNFα-mediated impairment of pTfh-induced IL-21
secretion is postulated. Interventions aimed at reducing chronic inflammation and immune activation in aging, HIV-
infected patients may improve their response to vaccines.
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Introduction
Infectious diseases take a massive toll on the well being of
both the elderly and the HIV-infected population [1,2]. The
situation is particularly concerning with regard to vaccine-
preventable diseases, with up to 1,000 times greater risk of
death in older adults compared to vaccine-aged children [3].
Indeed, the elderly (>65 yrs) account for 90% of the >35,000
affected by annual influenza epidemics [4,5]. HIV-infected
people are at a significantly higher risk than the general
population at all ages for acquiring seasonal influenza infection,
despite vaccination and virologic control with combination
antiretroviral therapy (cART) [6-8]. Seasonal influenza
vaccination is recommended for elderly as well as HIV-infected
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individuals to reduce influenza-related morbidity and mortality
[9], but immune response to influenza vaccination is frequently
impaired in both these high-risk populations [10-13]. With the
considerable increase in life expectancy of HIV-infected
persons with cART, and the increasing incidence of new HIV
infections at older ages, it is estimated that by 2015, 50% of
HIV-infected population will be ≥50 years of age [14]. Given the
independent detrimental effects of aging and of HIV infection
on the immune system [15-17], it is important to investigate the
cumulative effects of HIV and aging on immunity, e.g. as
assessed by responsiveness to seasonal influenza vaccines.
Although influenza vaccines elicit both cellular and humoral
responses [18], immune protection is largely correlated with
post-vaccination serum antibody (Ab) titers [19]. An essential
step in the generation of vaccine induced Ab-secreting B cells
is the interaction of antigen-primed B cells and T follicular
helper cells (Tfh) in the germinal center reaction, where Tfh
cells provide essential helper function for B cells to undergo
proliferation, isotype switching and somatic hypermutation
(reviewed in [20]). Tfh cells are characterized by surface
expression of the CXC chemokine receptor 5 (CXCR5), that
promotes their homing to lymphoid germinal centers [21], and
by abundant production of the cytokine interleukin (IL)-21, that
plays a major role in inducing B cell differentiation and
proliferation [22] and in preserving plasma cells [23,24].
Recently, a CD4 T memory cell subset in peripheral blood
bearing functional and partial phenotypic similarity to lymph
node Tfh has been identified and has been designated as
peripheral (p)Tfh [25-27]. The pTfh cells represent
approximately 15% of circulating CD4 T cells in humans [27],
express CXCR5 and provide critical help to B cells for antibody
secretion in an IL-21-dependent manner [26]. In a study of
vaccine responses to the pandemic H1N1/09 influenza vaccine
in HIV infected young patients, impaired vaccine responses
were associated with defective function of pTfh and in the
IL-21/IL-21R system [27,28]. In physiologic aging, impaired Ab
responses to seasonal influenza vaccination have been largely
attributed to intrinsic B and T cell defects [29-33], but pTfh have
not been investigated.
A common feature of both HIV/AIDS and aging is the
associated inflammation and immune activation of varying
degrees [34,35], which is nevertheless greater in HIV-infected
individuals than in age-matched uninfected controls, as we
recently demonstrated in a cohort of post-menopausal women
[36]. Tumor necrosis factor (TNF)α, one of the first pro-
inflammatory factors that was described in HIV infection [37], is
elevated also in the elderly [38,39], and its increased levels
have been associated with disease progression and treatment
failure in HIV-infected patients [40-42], and with increased risk
for atherosclerosis in the aging population [43]. Intriguingly, this
cytokine has been reported to decrease both T and B cell
responses in vitro [44-46]. Excessive immune activation is
known to favor disease progression and to hinder CD4 T cell
immune reconstitution in HIV-infected persons [47-49]. In this
study we have demonstrated that immune activation and the
proinflammatory cytokine TNFα can have a detrimental effect




Women were considered eligible if they were older than 45
years of age, had been amenorrheic for ≥12 months, were not
receiving hormonal replacement therapy, steroids,
immunosuppressant medications, and did not have active
malignancies. HIV infection was documented by licensed EIA
and, if needed, confirmatory western blotting prior to
enrollment. The study protocol and the informed consent forms
were approved by the University of Miami Institutional Review
Board and participants were enrolled after written informed
consent was obtained. The study population included 12 HIV-
uninfected (HIV–) and 16 HIV-infected (HIV+) women on ART
with virologic suppression (HIV RNA <100 copies/ml) for ≥6
months prior, median CD4 count of 519 cells/mm3 (190-1,046
cells/mm3), and median nadir CD4 count of 124 cells/mm3
(4-249 cells/mm3). ART included two nucleoside reverse
transcriptase inhibitors with either a Ritonavir boosted protease
inhibitor, the non-nucleoside reverse transcriptase inhibitor
Efavirenz or the integrase inhibitor Raltegravir. HIV+ and HIV–
women were matched for age and time to menopause.
Characteristics of the study population are summarized in
Table S1.
Study participants were given a single non-adjuvanted dose
of the 2011-2012 recommended influenza vaccine, containing
15 μg hemagglutinin of each of the following strains: A/
California/7/2009 (H1N1), A/Perth/16/2009 (H3N2) and B/
Brisbane/60/2008 (FLUARIX® from GSK, UK). Vaccine
preparation included the same viruses that were used for the
2010-2011 influenza season. Eighteen participants (5 HIV– and
11 HIV+) had been vaccinated in the previous season whereas
vaccination history was unavailable in the remainder. None had
influenza symptoms at enrollment or follow up.
Processing of blood samples
Peripheral venous blood was collected by venipuncture into
heparinized tubes at pre-vaccination (t0) and four weeks post-
vaccination (wk4). Blood samples were processed immediately
after collection. Peripheral blood mononuclear cells (PBMC)
were isolated by Ficoll-hypaque density sedimentation,
cryopreserved in FBS + 10% DMSO and stored in liquid
nitrogen; plasma was stored at -80°C.
Serological assessments
Hemagglutination inhibition assay (HIA).  Antibody titers
specific for the whole vaccine were determined in t0 and wk4
plasma samples by HIA [50]. Whole vaccine was used instead
of the individual antigens because the Ab titers were
comparable to those seen against the individual viral strains
[32]. Briefly, receptor-destroying enzyme (Denka Seiken,
Campbell, CA) was added to the plasma samples to remove
nonspecific inhibitors, incubated overnight at 37°C, and heat
inactivated at 56°C for 1 hour. For each sample, a two-fold
serial dilution was incubated with an equal volume (25 μl) of 4
hemagglutinin units of the same vaccine that was given to
study participants (FLUARIX®, GSK) for 1 hour at room
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temperature. Fifty μl of 1% suspension of chicken red blood
cells (Rockland™, Gilbertsville, PA) were added to each well,
and antibody titers were determined 2 hours later. Paired pre-
and post-vaccination samples from the same donor were
tested simultaneously; each serial dilution was performed in
triplicate. Seroprotection was defined as a vaccine-specific Ab
titer ≥1:40, seroconversion was defined as a ≥4-fold increase in
post-vaccination titers.
Multiplex plasma cytokine measurement.  TNFα, IL-6 and
IL-8 plasma levels were measured using a customized
MILLIPLEX™ Cytokine Human Ultrasensitive magnetic bead
panel (EMD Millipore, Billerica, MA). Undiluted samples were
incubated overnight with cytokine-specific beads at 4°C with
shaking. After washing, biotinylated detection antibodies and
streptavidin-PE were subsequently added. The beads were
washed and acquired on a MAGPIX instrument (Luminex
Corporation, Austin, TX). Mean fluorescent intensity (MFI) data
were collected and analyzed with MILLIPLEX™ Analyst
Software (EMD Millipore).
Plasma IL-21 measurement.  IL-21 levels were measured in
undiluted plasma samples by ELISA (eBioscience, San Diego,
CA), following manufacturer’s protocol.
Multicolor flow cytometry
Monoclonal antibodies.  The following anti-human
monoclonal antibodies (MoAbs) were utilized for flow cytometry
studies: CD3 AmCyan, Ki-67 PerCPCy5.5, CXCR5 AF647,
IL-21R APC, CD20 APCCy7, CD21 PeCy5, CD27 AF700 and
PD-1 PECy5 from BD Biosciences (San Jose, CA); CD4
QDot655, CD8 QDot605, CD10 QDot605 and CD45RO ECD
from Invitrogen (Eugene, OR); HLA-DR AF488, CD38 PerCP,
CD28 FITC, FcRL4 PE and CD57 APC from BioLegend (San
Diego, CA). Live/Dead® Fixable Violet Dead Cell Stain (ViViD)
Kit (Invitrogen) was used for exclusion of dead cells.
Appropriate isotype control MoAbs were used for gating.
Immunophenotyping.  Cryopreserved PBMC were thawed
and rested overnight. One million cells were incubated with
ViViD stain and MoAbs for surface markers for 15 minutes,
washed, fixed, permeabilized with Cytofix/Cytoperm Buffer (BD
Biosciences), and stained for intracellular marker Ki-67 for 30
minutes. Cells were then washed, resuspended in PBS + 1%
paraformaldehyde and acquired on a BD Biosciences
LSRFortessa analyzer after proper instrument setting and
compensation [51,52]. At least 500,000 events in the
lymphocyte gate were acquired per sample. Data analysis was
performed using FlowJo platform (TreeStar, San Carlo, CA).
Frequencies of desired markers were determined in gated live
(ViViD–) cells. T cell populations were defined as follows: CD4
(CD3+CD4+), pTfh (CD3+CD4+CD45RO+CXCR5+, as described
in [26]) and CD8 (CD3+CD8+) cells. B cell differentiation
subsets, determined based on phenotypic characteristics
described by Moir and Fauci (reviewed in [53]) and also by us
[28], were defined as: early transitional (CD21lo/negCD27–
CD10+), late transitional (CD21hiCD27–CD10+), naïve
(CD21hiCD27–CD10–), resting memory (CD21hiCD27+CD10–),
activated memory (CD21lo/negCD27+CD10–), and exhausted
tissue-like (CD21lo/negCD27–CD10–).
Memory CD4+B cell co-cultures
Cell enrichment and culture.  B cells were isolated from
healthy donor PBMC by positive selection using the EasySep™
Human CD19 Positive Selection Kit (Stemcell Technologies,
Vancouver, Canada). From the remaining cells, memory
(CD45RA–) CD4 T cells were obtained by negative selection
with the EasySep™ Human Memory CD4 T Cell Enrichment Kit
(Stemcell Technologies). Purity of cell populations was
95-98%. B and memory CD4 T cells were co-cultured at a 1:1
ratio in duplicate wells. The following reagents were added to
the cultures: 200 ng/ml staphylococcal enterotoxin B (SEB,
Sigma-Aldrich), 50 ng/ml recombinant human (rh)TNFα, 2
μg/ml anti-human TNFα blocking antibody, 50 ng/ml rhIL-21
(Invitrogen), 20 μg/ml rhIL-21R-Fc chimera (R&D Systems,
Minneapolis, MN). Appropriate isotype Abs were used as
controls. Culture supernatants were tested for levels of IL-21
(day 3), IgM, IgG and IgA (day 7) using commercially available
ELISA kits (from eBioscience and Bethyl Laboratories,
respectively). Cells were phenotyped as described above.
Statistical analysis
Differences between groups were analyzed by Student’s t-
test, Mann-Whitney test, or one-way ANOVA according to data
distribution. Correlations between two variables were evaluated
by Pearson correlation and linear regression. Analyses were
performed using GraphPad Prism (GraphPad Software Inc, La
Jolla, CA). P values <0.05 were considered significant. Results
are presented as mean ± standard deviation.
Results
Response to the influenza vaccine
The reverse cumulative distribution curves in Figure 1A and
B show anti-influenza antibody titers before and 4 weeks after
vaccination, respectively. Immune responses to the influenza
vaccine were overall higher in the HIV– group as compared to
the HIV-infected group. Before vaccination (t0), 58% of the
HIV– and 31% of the HIV+ women had a protective Ab titer
(≥1:40), likely due to the persistence of antibodies generated
during previous influenza seasons [54] (Figure 1A). Four
weeks after vaccination (wk4), 92% of the HIV– women were
seroprotected, while only 75% of the HIV+ women had a
protective Ab titer (Figure 1B). The increase in vaccine-specific
Ab titer from baseline to wk4 post-vaccination was significant in
both HIV– and HIV+ women, but wk4 Ab titers were higher in
the HIV– group as compared to the HIV+ group (Figure 1C). The
seroconversion rate did not differ between HIV– and HIV+
women, with 50% of the HIV– and 37.5% of the HIV+ displaying
a ≥4 fold increase of Ab titer at wk4. However, the magnitude
of Ab response was significantly greater in the HIV– than in the
HIV+ women (Figure 1D).
Association between CD4 T cell activation and humoral
response to the influenza vaccine
The immune phenotype of HIV+ aging women consisted of
higher frequency of activated (CD38+HLA-DR+), replicating
(Ki-67+) CD4 and pTfh cells, and higher levels of activated and
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senescent (CD28–CD57+) CD8 T cells, as compared to the
HIV– controls (Table S2). There was an inverse correlation
between the frequency of activated CD4 and pTfh cells and the
Ab titer at wk4 post-vaccination, both in the HIV– and in the HIV
+ women (Figure 2A and B). An inverse correlation was
observed between wk4 Ab titers and the frequency of
senescent CD4 T lymphocytes in the uninfected group (Figure
2A). No association was observed between CD8 T cell
activation or senescence and post-vaccination Ab titers (Figure
2C). There was no association between CD4 or pTfh activation
and pre-vaccination Ab titers (not shown).
B cell alterations in HIV+ women are not associated with
Ab response to the influenza vaccine
In HIV infection, B cell abnormalities in both subsets
distribution and phenotype markers have been associated with
altered effector function [55]. Pre-vaccination frequencies of B
cell differentiation subsets determined in HIV-uninfected and
infected aging women are depicted in Figure 3A. B cell
distribution into differentiation subsets in HIV+ patients differed
from uninfected controls as previously described [28,56].
Expression of the inhibitory receptor FcRL4 was found to be
higher in several B cell subsets in the HIV+ group as compared
to the HIV– controls (Figure 3B). No significant changes were
observed at wk4 post vaccination in relation to t0 (not shown).
In contrast to what shown for CD4 and pTfh activation status
(Figure 2A and B), no association between B cell alterations
and wk4 influenza Ab titers were observed in HIV-uninfected or
infected donors (Figure 3C).
TNFα plasma levels inversely correlate with Ab
response to the influenza vaccine, and are associated
with CD4 T and pTfh cell activation
We sought to investigate the relation between levels of
proinflammatory cytokines TNFα, IL-6 and IL-8 (see Table S2
for pre-vaccination levels of these cytokines) and magnitude of
Figure 1.  Antibody response to influenza vaccination.  Antibody titers specific for the whole 2011-2012 seasonal influenza
vaccine were determined before (t0) and 4 weeks (wk4) after vaccination by hemagglutination inhibition assay in the plasma of 12
HIV– and 16 HIV+ elderly women. Reverse cumulative distribution curves for the antibody titers prior to (A) and 4 weeks after (B)
vaccination for HIV-uninfected (open circles) and HIV-infected (filled circles) donors were derived to illustrate immune responses.
(C) Reciprocal of Ab titers before and after vaccination. (D) Ratio between the wk4 and the baseline reciprocal of Ab titer. P values
were calculated with Student’s t-test or Mann-Whitney test as appropriate.
doi: 10.1371/journal.pone.0079816.g001
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Figure 2.  T cell activation and senescence are associated with decreased humoral response to influenza
vaccination.  Frozen PBMC obtained before influenza vaccination were thawed, rested over night and stained with monoclonal
antibodies for immunophenotyping of CD4 (ViViD-CD3+CD4+), pTfh (ViViD-CD3+CD4+CD45RO+CXCR5+) and CD8 (ViViD-
CD3+CD8+) T cell subsets. Correlations were established between the reciprocal of influenza Ab titer at week 4 and the frequency of
activated (CD38+HLA-DR+), dividing (Ki-67+) and senescent (CD28-CD57+) CD4 (A), pTfh (B) and CD8 (C) T cells for 10 HIV– (open
dots) and 15 HIV+ (filled dots) post-menopausal women. Pearson analysis was utilized to establish statistical correlation between
variables.
doi: 10.1371/journal.pone.0079816.g002
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antibody response to the influenza vaccine. In both HIV– and
HIV+ donors, pre-vaccination plasma TNFα levels correlated
inversely with wk4 Ab titers (Figure 4A), directly with the
frequency of activated and dividing CD4 and pTfh cells (Figure
4B and C), and did not show an association with frequencies of
senescent CD4 and CD8 T cells (Figure 4B and D), or with
CD8 T cell activation (Figure 4D). No association was observed
between Ab titer and IL-6 or IL-8 plasma levels, or with altered
B cell subsets observed in Figure 3A and B (not shown).
Figure 3.  Phenotypic alterations in B cell subsets in HIV-infected aging women are not associated with antibody response
to influenza vaccination.  PBMC were stained with surface MoAbs to CD20, CD21, CD10, CD27 and FcRL4. Lymphocytes were
gated based on forward and side scatter. CD3-CD20+ cells were gated into CD21hi and CD21lo/neg cells and further divided based on
the expression of CD27 and CD10 as: early transitional (CD21lo/negCD27-CD10+), late transitional (CD21hiCD27-CD10+), naïve
(CD21hiCD27-CD10–), resting memory (CD21hiCD27+CD10–), activated memory (CD21lo/negCD27+CD10–), and exhausted tissue-like
(CD21lo/negCD27-CD10–) subsets. (A) The percentage of cells in each B cell subpopulation was determined in 10 healthy controls
(open dots) and 15 HIV-infected women (filled dots) before vaccination. (B) Expression of the exhaustion marker FcRL4 was
evaluated in each B cell subset. (C) Correlations were established between the B cell populations that resulted significantly different
between HIV- and HIV+ in A and B and the reciprocal of influenza Ab titer at week 4. Correlation between variables was established
with Pearson analysis.
doi: 10.1371/journal.pone.0079816.g003
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Figure 4.  Association between circulating levels of TNFα, Ab response to influenza vaccination and T cell activation and
senescence.  (A) Correlation between TNFα plasma levels at t0 and the reciprocal of vaccine-specific Ab titers at week 4 was
established for 12 HIV– and 14 HIV+ aging women. Plasma TNFα levels were measured using a customized MILLIPLEX™ Cytokine
Human Ultrasensitive magnetic bead panel (EMD Millipore). (B-D) T cells were immunophenotyped using MoAbs specific for
activation (CD38, HLA-DR), proliferation (Ki-67) and senescence (CD28, CD57) markers. Frequencies of CD4, pTfh and CD8 T cell
subsets expressing these markers were correlated with pre-vaccination TNFα plasma levels. Statistical analysis was performed
using Pearson correlation.
doi: 10.1371/journal.pone.0079816.g004
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TNFα promotes T cell activation and impairs the
secretion of IL-21 and immunoglobulins in vitro
Since high pre-vaccination plasma levels of TNFα were
associated with pTfh activation status and low Ab response to
the influenza vaccine (Figure 4A and C), we sought to
investigate the effect of TNFα on T and B cells in vitro. We
isolated memory CD4 T cells (as surrogates of pTfh cells) from
leukopacks of 4 young healthy donors [frequency of pTfh within
the purified memory CD4 T cells was comparable across all
donors (22.3±2.48%)] and co-cultured them with autologous B
cells in the presence of SEB. As expected, the addition of
exogenous TNFα increased the expression of activation
markers in both CD4 and pTfh cells (Figure 5A). Importantly,
the addition of exogenous TNFα to SEB-stimulated cultures
resulted in decreased IL-21 production, and maximum
secretion of IL-21 was detected in the presence of blocking
TNFα antibody (Figure 5B). Moreover, in the presence of SEB,
exogenous TNFα resulted in decreased immunoglobulin levels,
while TNFα blockade significantly increased immunoglobulin
production as compared to SEB alone (Figure 5C).
Immunoglobulin production increased in IL-21-supplemented
cultures, and it was drastically reduced in the presence of
IL-21R-Fc blocking Ab (Figure 5D). When IL-21 and TNFα
were simultaneously blocked, no differences in immunoglobulin
levels were observed as compared to the samples in which
only IL-21 was blocked (not shown).
Figure 5.  TNFα blockade promotes IL-21 secretion and IgG production in CD4-B cell co-cultures.  Memory CD4 T cells
obtained from 4 healthy donors were cultured with autologous B cells at a 1:1 ratio in the presence of SEB and/or TNFα, IL-21, anti-
anti-TNFα or anti-IL-21R blocking antibodies or the appropriate isotype control. (A) Phenotyping was performed on day 3 of co-
culture in gated live CD4 and pTfh cells. (B) IL-21 levels measured by ELISA in day 3 culture supernatants. (C, D) IgM, IgG and IgA
levels were evaluated by ELISA after 7 days of co-culture. In (D), IgG levels in samples where IL-21R-Fc was added were not
measurable because of the cross-reactivity to the Fc portion of IL-21R-Fc. P values were calculated using paired Student’s t-test for
comparisons between two groups, and repeated measures one-way ANOVA for comparisons between larger groups.
doi: 10.1371/journal.pone.0079816.g005
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Changes in the IL-21/IL-21R system associated with
antibody response to the influenza vaccine
We previously observed that a protective humoral response
to the influenza vaccine is associated with increased levels of
IL-21 and increased expression of IL-21R in B cells post-
vaccination [28]. Investigation of the IL-21/IL-21R system
revealed an increase in IL-21 plasma levels from t0 to wk4 in
those HIV– and HIV+ aging women who were seroprotected at
wk4, but not in the HIV+ non-seroprotected women (Figure 6A).
The post-vaccination plasma levels of IL-21 correlated with the
wk4 Ab titers (not shown). The increase in IL-21 plasma levels
from t0 to wk4 was inversely associated to the pre-vaccination
circulating levels of TNFα (Figure 6B). IL-21R MFI in CD4 T
cells pre-vaccination was significantly higher in HIV– as
compared to the HIV+ women, both in seroprotected and non-
seroprotected participants (Figure 6C). An increase in IL-21R
MFI from t0 to wk4 was detected only in CD4 T cells of
seroprotected women, while no changes in IL-21R MFI were
observed in CD4 T cells from non-seroprotected donors, or in
the CD8 T cell compartment of either SP or NSP donors
(Figure 6D). IL-21R expression was also increased post-
vaccination in B cells of seroprotected women, although not
significantly (not shown).
Discussion
Influenza infection is associated with significant morbidity
and mortality in the elderly and HIV-infected individuals,
underscoring the importance of effective vaccination-induced
protection for these populations. It is well established however
that both these high risk groups can have impaired influenza
vaccine responses [10,13,29-33]. Our present study in post-
menopausal women implies that the burden of HIV infection on
top of aging is likely to increase the risk for deficient influenza
vaccine responses in comparison to HIV uninfected aging
women. We describe the novel association of impaired vaccine
response to ongoing immune activation. In particular, we
demonstrate that an activated state of peripheral T follicular
helper cells and decreased vaccine-induced plasma IL-21, the
signature cytokine of Tfh, are associated with impaired
influenza-vaccine induced antibodies. We provide novel
experimental data implicating TNFα as a major contributor for
these deficiencies.
For selecting a clear functional state of aging, we performed
this study in post-menopausal women and thus avoided any
influence of perimenopausal hormonal fluctuations on
inflammation and immune activation. The study participants
were recipients of the 2011-2012 seasonal influenza vaccine,
which contained the same strains that had been included in the
2010-2011 vaccine composition [containing an A/California/
7/2009 (H1N1)-like virus, an A/Perth/16/2009 (H3N2)-like virus
and a B/Brisbane/60/2008-like virus]. In our study cohort, the
pre-vaccination influenza Ab titers were in the protective range
(≥1:40) in 58% of HIV– and 31% of HIV+ aging women,
presumably due to persisting or cross-reactive antibodies
resulting from previous infection or vaccination. Although
seroconversion rates were similar between HIV-infected and
uninfected women, they differed in the response to vaccination.
In the HIV+ women, antibody titers at wk4 and the fold increase
in titers from t0 were lower, with several showing <4 fold
increase in comparison to the HIV– control group, pointing to
less immune competence in the HIV-infected women.
To elucidate factors contributing to immune impairment, we
investigated the relationship between Ab responses and
cellular immune activation and inflammatory cytokines. Several
studies have previously shown that activated CD8 T cells are
associated with disease progression in HIV infection [48,49,57].
Interestingly, for the influenza vaccine-induced Ab response, it
was CD4 T cell activation rather than CD8 T cell activation that
showed this inverse relationship, suggesting that immune
activation may have different outcomes that are specific for
each cell type. Since among CD4 T cells, the pTfh subset
promotes B cell proliferation and maturation [25-27], we
investigated this subset and noted that the presence of
activated pTfh cells prior to vaccination had a strong negative
correlation with magnitude of post-vaccination Ab titers, both in
HIV-uninfected and HIV-infected donors. This observation
suggests that in an activated state, pTfh cells are less
competent in providing the needed help to B cells to
differentiate into Ab-producing cells, ultimately leading to
impaired Ab response to influenza vaccine.
Both aging and HIV infection can lead to excessive
inflammation. The inflammation that accompanies physiologic
aging has disparate etiologies including, but not limited to,
hormonal changes, diet, environmental and genetic causes.
We have recently reported that in the post-menopause state
several measures of immune activation and inflammation,
notably T cell activation and exhaustion, monocyte/
macrophage activation, and proinflammatory cytokines IL-6,
IL-8 and TNFα, were higher in HIV+ women as compared to
HIV-uninfected controls [36]. The drivers of immune activation
in HIV disease in virally suppressed individuals are not well
understood, but may include microbial translocation due to
persistent virus-induced injury in gut-associated lymphoid
tissue [58]. However, no association between markers of
microbial translocation (circulating levels of LPS, monocyte/
macrophage activation marker sCD14) and magnitude of
antibody response to the influenza vaccine was observed in
our study cohort (data not shown). Levels of plasma TNFα had
a significant negative relationship with vaccine-specific Ab titers
at week 4 post-vaccination in both HIV– and HIV+ aging women.
Prolonged TNFα exposure is known to impair T cell responses
(namely TCR-induced proliferation and cytokine production) by
attenuating T cell receptor signaling [44,45], and anti-TNF
therapy in patients with psoriasis and inflammatory bowel
disease results in improved responses to TCR stimulation ex
vivo [59]. We investigated the influence of TNFα experimentally
by adding it to cell cultures and noted that it could lead to
upregulation of activation markers on CD4 T cells including
pTfh cells. TNFα blockade in co-cultures of purified memory
CD4 T cells and B cells enhanced Ab production supporting the
contention that TNFα has a negative influence on Ab
responses. Additionally, TNFα can potentially inhibit B cells
directly as suggested by studies in mice [46] and by the
observation that B cells of aging individuals can secrete TNFα
with intrinsic inhibition of their function [60].
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The helper function of Tfh and pTfh cells is mediated by
cognate interaction with B cells and IL-21 secretion
[25-27,55,61]. We previously demonstrated in young HIV+
adults who responded to influenza vaccine that their plasma
IL-21 levels increased with upregulation of IL-21R in B cells,
while vaccine non-responders failed to do either [28]. In the
present study as well, we observed higher plasma IL-21 levels
only in participants who were seroprotected at week 4, and
frequency of IL-21R expression in CD4 T cells was also higher
in these individuals. These findings expand the role of the
IL-21/IL-21R system in regulating vaccine responses by
activities not only in the B- but also in the CD4 T cell
compartment. A trend of IL-21R upregulation in B cells was
also observed, even though it did not reach statistical
significance likely due to small sample size. Interestingly,
IL-21R levels in CD8 T lymphocytes remained unaltered,
implying that mechanisms other than IL-21 are involved in the
generation of influenza-specific CD8 T cells. We have
Figure 6.  Increased plasma IL-21 and IL-21R expression in CD4 T cells is associated with humoral response to the
influenza vaccine.  (A) Circulating levels of IL-21 were measured by ELISA at t0 and wk4 in the plasma of 11 HIV– seroprotected
(HIV– SP), 12 HIV+ seroprotected (HIV+ SP) and 4 HIV+ non seroprotected (HIV+ NSP) post-menopausal women. (B) Correlation
between TNFα plasma levels at baseline and the ratio between wk4 and baseline plasma IL-21. (C, D) IL-21R mean fluorescence
intensity (MFI) was established in live CD4 (C) and CD8 (D) T cells of 8 HIV– SP, 11 HIV+ SP and 4 HIV+ NSP aging women. Frozen
cells obtained before and four weeks after vaccine administration were thawed, rested overnight, stained for surface markers and
acquired by flow cytometry. IL-21R MFI was established for ViViD-CD3+CD4+ or ViViD-CD3+CD8+ events. Statistical analysis was
performed using paired Student’s t-test for comparisons within groups, unpaired Student’s t-test for comparisons between groups,
and Pearson correlation as appropriate.
doi: 10.1371/journal.pone.0079816.g006
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previously shown that the pTfh CD4 T cell subset resides
almost exclusively in the memory CD4 T cell pool and that
IL-21 production by pTfh is critical for influenza Ab response
[27]. Here we demonstrated that addition of TNFα resulted in
decreased IL-21 secretion in CD4 cell cultures, whereas IL-21
addition in our experimental model resulted in increased Ig
production. As expected, IL-21 blockade resulted in
suppressed Ig production based on the known critical role of
IL-21 in supporting B cell function [22-24]. Taken together, our
findings imply that excessive TNFα can impair pTfh function
and IL-21 secretion, resulting in deficient help to B cells and
poor Ab responses. Lack of clinical samples precluded us from
doing experiments to investigate the mechanism of TNF alpha
on adaptive immune responses in co-culture studies. We
cannot exclude the possibility that in vivo, the decreases in
IL-21 and antibody secretion iresulted from death of activated
cells or a direct inhibitory effect of TNF-alpha on B cells.
Previous studies have implicated immune senescence for
failure to respond to influenza vaccination [62,63].
Accumulation of senescent lymphocytes has also been
reported for HIV-infected individuals [64,65], possibly as
consequence of chronic antigenic stimulation. We observed
that senescent CD4 and CD8 T cells in our cohort were in
higher frequency in HIV+ women. Since senescent T
lymphocytes are characterized by lack of the costimulatory
signal transduced by CD28, decreased ability to secrete IL-2
upon activation and poor proliferative capacity (reviewed in
[66]), it is not surprising that accumulation of these cells is
associated with decline of the immune function and poor
humoral response to influenza vaccination. B cell exhaustion
and loss of memory B cells in HIV-infected adults [67] have
been associated with impaired humoral response to influenza
vaccination. In our cohort alterations in B cell subsets
distribution and increased B cell exhaustion (FcRL4) were
observed in HIV+ as compared to the uninfected participants.
However, no significant association between vaccine-specific
Ab titers and these B cell abnormalities was observed in this
cohort. Moreover, the fact that no correlation between altered B
cell subsets and TNFα levels was observed suggests that the
overriding defect is that of TNFα-derived excessive T cell
activation.
Limitations of this pilot study are the small sample size,
absence of data for other causes of immune activation such as
chronic co-infections e.g. with CMV, HCV [68,69], and
possibility of residual HIV replication despite virus suppression
[70], and the lack of a study group composed of young HIV-
infected and uninfected donors, that would have allowed to
dissect the effects of aging versus HIV infection on the immune
response to influenza vaccine. Moreover, Ab titers were
established for the whole vaccine rather than for its three
individual components, possibly underestimating the
contribution of the specific strains to the seroprotection levels
of the donors. Nevertheless, this is the first study to focus on
influenza vaccine-induced Ab responses in the context of aging
and HIV infection and immune activation. The novel finding
reported herein is the association of activated pTfh and
impaired IL-21 production, with negative correlation of TNFα
with poor Ab responses. Elevated plasma TNFα levels are
present in HIV– aging population as well as in young HIV+
individuals [35,71]. Our results provide a rationale to further
evaluate the role of pTfh in vaccine response in elderly HIV+
individuals and in other proinflammatory conditions where
abnormal antibody responses are observed upon vaccination.
Interventions aimed to reduce chronic inflammation and
activation in HIV-infected patients may improve their response
to vaccination. Studies in larger cohorts may help to define
predictive immunologic signatures of vaccine responses.
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